Correlation of pretreatment serum tissue polypeptide specific antigen (TPS) with prognosis in primary breast cancer
- Author:
- No author available
- Journal Title:
- CHINESE-GERMAN JOURNAL OF CLINICAL ONCOLOGY
- Issue:
- 11
- DOI:
- 10.1007/s10330-012-1060-3
- Key Word:
- breast neoplasms;serum;tumor markers;biological;prognostic factor
Abstract： Objective: The aim of this study was to explore the correlation of pretreatment serum tissue polypeptide specific antigen (TPS) with prognosis in primary breast cancer. Methods: A total of 361 patients with grades Ⅰ-Ⅲ breast cancer had been followed up from January 2001 to February 2011. Serumal TPS level was measured by enzyme-linked immunosorbent assays (ELISA). Univariate and multivariate analyses were used to investigate associations between pretreatment TPS level and clinicopathological parameters and patient outcomes. Results: First, at the univariate analysis, the expression of TPS was related with some clinicopathological traditional prognostic factors such as tumor size (P = 0.030), histologic grade (P = 0.001) and lymph node status (P = 0.008). Second, overall survival were significantly shorter among patients with elevated pretreatment serum TPS (P = 0.038). However, finally, multivariate Cox regression indicated that the level of pretreatment serum TPS was not an independent prognostic parameter for overall survival in primarily breast cancer patients (P > 0.05). Conclusion: The expression of pretreatment serum TPS is closely correlated with clinicopathology parameters and overall survival of patients with primarily breast cancer, but its level has no independent prognostic value.
- [1]C, Arciero,S B, Somiari,C D, Shriver,etc.Functional relationship and gene ontology classification of breast cancer biomarkers.[J].1900,18.
- [2]Paccagnella A,Rosabian A,Biganzoli E,etc.Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: a prognostic marker possibly associated with apoptosis.[J].2000,59(3).
- [3]Molina R,Goike H,Nap M,etc.Tumor Markers in Breast Cancer - European Group on Tumor Markers Recommendations.[J].2005,26(6).
- [4]L, Rydlander,E, Ziegler,T, Bergman,etc.Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18.[J].1996,241.
- [5]Catharine M, Sturgeon,Michael J, Duffy,Ulf-H?kan, Stenman,etc.National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.[J].2008,54(12).
- [6]Jemal,A.,Naishadham,D.,Siegel,R..Cancer statistics, 2012[J].2012,62(1).
- [7]Xiaodong,XIE,FANG,etc.The clinical significance of hMAM mRNA expression in peripheral blood of patients with breast cancer[J].2008,007 (12).
- [8]Peretz T,Heching N,Amir G,etc.Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.[J].1999,19(4C).
- [9]Uehara M,Kinoshita T,Hojo T,etc.Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer.[J].2008,13(5).
- [10]Yoo KY,Ahn SH.Chronological changes of clinical characteristics in 31,115 new breast cancer patients among Koreans during 1996-2004.[J].2006,99(2).
- [11]Speers,C.,Yerushalmi,R.,Kennecke,H.,etc.Tumor markers in metastatic breast cancer subtypes: Frequency of elevation and correlation with outcome[J].2012,23(2).
- [12]Sheard MA,Valik D,Vojtesek B,etc.Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis.[J].2002,85(4).
- [13]M, Giai,R, Roagna,R, Ponzone,etc.TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.[J].1900,16.
- [14]K, Bremer,G, Eklund,B, Bj?rklund.Notable relationship between the level of tumor marker TPS in serum and survival in breast cancer.[J].1900,16(2).